Design Therapeutics Inc
NASDAQ:DSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Design Therapeutics Inc
Free Cash Flow
Design Therapeutics Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Design Therapeutics Inc
NASDAQ:DSGN
|
Free Cash Flow
-$54.6m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-215%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Free Cash Flow
$17.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
1%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Free Cash Flow
$9.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Free Cash Flow
$8.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Free Cash Flow
$3.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Free Cash Flow
$3.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
19%
|
|
Design Therapeutics Inc
Glance View
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. The company is headquartered in Carlsbad, California and currently employs 37 full-time employees. The company went IPO on 2021-03-26. The firm is focused on gene-targeted chimeras (GeneTAC) molecules, which is a class of small-molecule gene-targeted chimera therapeutic candidates that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. The firm's lead product candidate is Friedreich ataxia (FA). The firm is also developing the GeneTAC program in myotonic dystrophy type-1 (DM1), and it is advancing its GeneTAC portfolio to address other serious nucleotides repeat-driven monogenic diseases. Its FA is a monogenic, autosomal recessive progressive disease. Its DM1 is a monogenic, autosomal dominant, progressive neuromuscular disease that affects skeletal muscle, heart, brain and other organs.
See Also
What is Design Therapeutics Inc's Free Cash Flow?
Free Cash Flow
-43.4m
USD
Based on the financial report for Dec 31, 2024, Design Therapeutics Inc's Free Cash Flow amounts to -43.4m USD.
What is Design Therapeutics Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-215%
Over the last year, the Free Cash Flow growth was 26%. The average annual Free Cash Flow growth rates for Design Therapeutics Inc have been -12% over the past three years , -215% over the past five years .
